ISIS Pharmaceuticals, Inc. Share Price Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 898.86Cr 785.52Cr 724.85Cr 668.13Cr 1.26TCr 87TCr 1.29TCr 8.66TCr 3.41TCr 42TCr 3.38TCr 3.3TCr 1,45900Cr | P/E 2026 * |
-15x | P/E 2027 * | -29.6x |
|---|---|---|---|---|---|
| Enterprise Value | 873.61Cr 763.45Cr 704.49Cr 649.37Cr 1.22TCr 84TCr 1.25TCr 8.42TCr 3.31TCr 41TCr 3.28TCr 3.21TCr 1,41800Cr | EV / Sales 2026 * |
9.82x | EV / Sales 2027 * | 6.41x |
| Free-Float |
99.09% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 01/07/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 01/01/2020 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 01/05/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 13/12/2005 |
| Director/Board Member | 73 | 01/05/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 25/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 898.86Cr | |
| +3.90% | -0.39% | +376.72% | +599.59% | 3.96TCr | |
| -1.70% | +4.46% | +7.46% | +57.67% | 3.47TCr | |
| -2.01% | -0.76% | +26.35% | -6.83% | 3.44TCr | |
| +0.06% | +0.34% | +2.32% | +29.30% | 2.71TCr | |
| +0.46% | -3.49% | - | - | 1.62TCr | |
| -0.04% | -0.09% | +68.48% | +117.39% | 1.54TCr | |
| +1.12% | +1.91% | +15.90% | +19.65% | 1.41TCr | |
| 0.00% | +1.36% | +15.74% | -30.62% | 1.3TCr | |
| -0.08% | -3.01% | +1,271.69% | +649.69% | 1.18TCr | |
| Average | +0.30% | +0.04% | +223.08% | +179.48% | 2.29TCr | |
| Weighted average by Cap. | +0.29% | +0.36% | +171.43% | +187.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 89Cr 78Cr 72Cr 66Cr 124.57Cr 8.56TCr 127.34Cr 857.05Cr 337.1Cr 4.19TCr 333.93Cr 326.6Cr 14TCr | 138.86Cr 121.35Cr 111.97Cr 103.21Cr 194.54Cr 13TCr 198.86Cr 1.34TCr 526.42Cr 6.55TCr 521.47Cr 510.03Cr 23TCr |
| Net income | -60Cr -52Cr -48Cr -44Cr -84Cr -5.76TCr -86Cr -576.61Cr -226.79Cr -2.82TCr -224.66Cr -219.73Cr -9.71TCr | -31Cr -27Cr -25Cr -23Cr -43Cr -2.98TCr -44Cr -298.13Cr -117.26Cr -1.46TCr -116.16Cr -113.61Cr -5.02TCr |
| Net Debt | -25Cr -22Cr -20Cr -19Cr -35Cr -2.43TCr -36Cr -243.36Cr -96Cr -1.19TCr -95Cr -93Cr -4.1TCr | -8.62Cr -7.53Cr -6.95Cr -6.4Cr -12Cr -829.72Cr -12Cr -83Cr -33Cr -406.36Cr -32Cr -32Cr -1.4TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
